Bioventus Inc.
NASDAQ:BVSMedical - Devices
+$0.18 today
- Market cap
- $727.20M
- Beta
- 0.67
- P/E (TTM)
- 20.6
- EPS (TTM)
- $0.42
Volume 0.70M
Average 0.56M
BVS EBITDA Margin
EBITDA as a percentage of revenue.
Bioventus Inc.NASDAQ: BVS
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 15.2%
EBITDA Margin was 15.2% in Q1 FY2026, up 2.3 pp from a year earlier. On a trailing-twelve-month basis it was 17.9%, up 11.6 pp year over year. Over 3 fiscal years it widened by 41.2 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 22.8% for the fiscal year ending Dec 2026, up from 17.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 15.2%-4.5 pp QoQ
- Last fiscal yearDec 2025
- 17.5%+10.6 pp YoY
- LTMMar 2026
- 17.9%+11.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.3 pp | +0.9 pp | -1.4 pp |
| 1 year | +10.6 pp | +5.3 pp | -5.3 pp |
| 3 years | +41.2 pp | +7.0 pp | -34.3 pp |
| 5 years | +3.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 17.5%
- Year-over-year change
- +10.6pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.5% | +10.6pp |
| FY2024 | 2024-12-31 | 6.8% | +11.3pp |
| FY2023 | 2023-12-31 | -4.5% | +19.2pp |
| FY2022 | 2022-12-31 | -23.7% | -34.3pp |
| FY2021 | 2021-12-31 | 10.6% | — |
EBITDA Margin vs competitors
How BVS compares with its peers on the latest reported figures
- BVS's LTM Mar 2026 EBITDA Margin of 17.9% is the 2nd highest of the 9 companies compared; the peer median is 8.5%.
- Its year-over-year change of +11.6 pp is the 3rd highest of 9, against a peer median of +1.7 pp.
- Over three fiscal years its change of +41.2 pp compares with a peer median of +1.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | 21.7% | -1.3 pp | -0.4 pp | |
| LTM Mar 2026 | 17.9% | +11.6 pp | +41.2 pp | |
| LTM Mar 2026 | 14.7% | -3.3 pp | +23.8 pp | |
| LTM Mar 2026 | 11.5% | +13.4 pp | -6.1 pp | |
| LTM Mar 2026 | 9.7% | +12.3 pp | +21.2 pp | |
| LTM Mar 2026 | 7.3% | +8.1 pp | +4.2 pp | |
| LTM Mar 2026 | -4.0% | -3.6 pp | -19.7 pp | |
| LTM Mar 2026 | -17.6% | -28.7 pp | -44.6 pp | |
| LTM Jun 2026 | -41.4% | +4.7 pp | +54.0 pp | |
| Peer median (excluding BVS) | 8.5% | +1.7 pp | +1.9 pp | |
Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 430.9M | 512.12M | 512.35M | 573.28M | 568.09M |
| Cost of Revenue | 128.19M | 181.04M | 184.15M | 185.05M | 185.66M |
| Gross Profit | 302.71M | 331.08M | 328.19M | 388.23M | 382.43M |
| Gross Margin | 70.3% | 64.6% | 64.1% | 67.7% | 67.3% |
| Research & Development | 19.04M | 23.85M | 13.45M | 13.64M | 12.11M |
| Selling, General & Admin | 254.25M | 332.13M | 303.88M | 327.09M | 311.77M |
| Operating Expenses | 290.65M | 498.31M | 409.92M | 400.21M | 323.88M |
| Depreciation & Amortization | 34.88M | 55.4M | 57.37M | 49.56M | 47.01M |
| EBITDA | 45.48M | (121.61M) | (23.07M) | 39.22M | 99.21M |
| EBITDA Margin | 10.6% | -23.7% | -4.5% | 6.8% | 17.5% |
| Operating Income | 12.06M | (167.23M) | (81.73M) | (11.98M) | 58.55M |
| Operating Margin | 2.8% | -32.7% | -16.0% | -2.1% | 10.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.11M | 12.02M | 40.68M | 38.79M | 26.49M |
| Other Income / Expenses | (2.57M) | (21.79M) | (39.39M) | (37.15M) | (32.84M) |
| Income Before Tax | 9.49M | (189.03M) | (121.11M) | (49.13M) | 25.71M |
| Pre-Tax Margin | 2.2% | -36.9% | -23.6% | -8.6% | 4.5% |
| Income Tax Expense | (1.97M) | (44.37M) | 85K | (5.29M) | (1.57M) |
| Net Income | 19.38M | (158.7M) | (156.23M) | (33.54M) | 22.73M |
| Net Margin | 4.5% | -31.0% | -30.5% | -5.9% | 4.0% |
| EPS (Basic) | (0.15) | (2.59) | (2.49) | (0.52) | 0.34 |
| EPS (Diluted) | (0.15) | (2.59) | (2.49) | (0.52) | 0.33 |
| Weighted Avg Shares | 45.47M | 61.39M | 62.65M | 65.36M | 66.62M |
| Weighted Avg Shares (Diluted) | 45.47M | 61.39M | 62.65M | 65.36M | 68.91M |
Bioventus Inc.
NASDAQ:BVS
Intrinsic Alpha fair value
Locked
Current Price
$10.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.